Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Net Income | -566.50K | -348.30K | -163.80K | -303.20K | -165.70K |
| Total Depreciation and Amortization | 9.10K | 9.80K | 3.50K | 300.00 | 11.70K |
| Total Amortization of Deferred Charges | 11.20K | 11.70K | 13.20K | 11.30K | -- |
| Total Other Non-Cash Items | 319.70K | 190.40K | 264.50K | 269.80K | -25.20K |
| Change in Net Operating Assets | 49.90K | -37.30K | -120.20K | -143.40K | 99.70K |
| Cash from Operations | -176.70K | -173.70K | -2.90K | -165.20K | -79.30K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -866.90K | -17.80K | -34.00K | -34.80K | -56.50K |
| Cash from Investing | -866.90K | -17.80K | -34.00K | -34.80K | -56.50K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.59M | 42.50K | 0.00 | 755.00K | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -31.10K | -- | -25.90K | -27.00K | -- |
| Cash from Financing | 1.09M | 30.90K | -18.90K | 534.20K | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 46.70K | -160.50K | -55.80K | 334.20K | -135.80K |